Evidence map›Paper›PMID 38352315›Full record

ArticlebioRxiv : the preprint server for biology2024

A general platform for targeting MHC-II antigens via a single loop.

Haotian Du, Jingjia Liu, Kevin M Jude, Xinbo Yang, Ying Li, Braxton Bell, Hongli Yang, Audrey Kassardjian, Ali Mobedi, Udit Parekh and 5 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Haotian DuDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Jingjia LiuDepartment of Bioengineering, Stanford University, CA, USA.
Kevin M JudeDepartments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Xinbo YangDepartments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.
Ying LiDepartment of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, USA.
Braxton BellDepartment of Chemistry, Stanford University, Stanford, CA, USA.
Hongli YangDepartment of Bioengineering, Stanford University, CA, USA.
Audrey KassardjianProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON M5G 0A4, Canada.
Ali MobediDepartment of Bioengineering, Stanford University, CA, USA.
Udit ParekhDepartment of Bioengineering, Stanford University, CA, USA.
R Andres Parra SperbergDepartment of Bioengineering, Stanford University, CA, USA.
Jean-Philippe JulienProgram in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON M5G 0A4, Canada.
Elizabeth D MellinsDepartment of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0003-2577-139X
K Christopher GarciaDepartments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID 0000-0001-9273-0278
Po-Ssu HuangDepartment of Bioengineering, Stanford University, CA, USA.ORCID 0000-0002-7948-2895

Funding

cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine75N93022D00005 · NIAID · INTERNATIONAL AIDS VACCINE INITIATIVE · PI HASSELL, THOMAS · 2022 to 2025
$8.0M
Structural correlates of T cell receptor signalingR01AI103867 · NIAID · STANFORD UNIVERSITY · PI Kenan Christopher GARCIA · 2014 to 2026
$5.3M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
MHC Variation in Host Response to SARS-CoV2 and COVID-19 OutcomesR01AI159260 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOLLENBACH, JILL ALLISON · 2021 to 2025
$4.0M
Generative neural networks for structure-based antibody designR01GM147893 · NIGMS · STANFORD UNIVERSITY · PI Possu Huang · 2022 to 2026
$1.9M
NHLBI NIH HHS 75N92020D00005NIAID NIH HHS 75N93022D00005NIAID NIH HHS 75N93023D00005NIAID NIH HHS R01 AI103867NIAID NIH HHS R01 AI159260NIDA NIH HHS 75N95020D00005NIGMS NIH HHS R01 GM147893ORFDO NIH HHS 75N99020D00005
6 · The paper itself

Abstract

Class-II major histocompatibility complexes (MHC-IIs) are central to the communications between CD4+ T cells and antigen presenting cells (APCs), but intrinsic structural features associated with MHC-II make it difficult to develop a general targeting system with high affinity and antigen specificity. Here, we introduce a protein platform, Targeted Recognition of Antigen-MHC Complex Reporter for MHC-II (

Identifiers

PMID38352315
PMCPMC10862749

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.